Supplementary Table 1.

Patient Eligibility for eINDs for use of COVID-19 convalescent plasma to treat patients (Adapted from FDA)

Diagnostic criteria fulfillment	Laboratory confirmed COVID-19
Clinical/laboratory criteria	Severe disease is defined as one or more of the following: Shortness of breath (dyspnea), Respiratory frequency ≥ 30/min, Blood oxygen saturation ≤ 93%, Partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, Lung infiltrates > 50% within 24 to 48 hours Life-threatening disease is defined as one or more of the following: Respiratory failure, Septic shock, Multiple organ dysfunction or failure
Consent	Informed consent provided by the patient or healthcare proxy.

Adapted from https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma ( Accessed on 06-02-2020)